Olema Pharmaceuticals appoints Dr. Prakash Raman to Board of Directors

Olema Pharmaceuticals, Inc.

Dr. Raman appointed as Class II director effective April 28, 2026; term expires at 2028 annual meeting.
He brings over 20 years of biopharma experience; currently CEO of InduPro Therapeutics.
Received initial equity grants: option for 24,150 shares vesting monthly over 3 years, plus 2,911 shares vesting June 11, 2026.
Company highlights lead program palazestrant in two Phase 3 trials with OPERA-01 data expected fall 2026.
Board determined Dr. Raman is independent under Nasdaq rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Prakash Raman

Class II director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2026-04-28
Filed: April 29, 2026, 7:59 PM ET

the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Prakash Raman was appointed as Class II director at Olema Pharmaceuticals, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026

View on SEC.gov

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-191944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.